PPT-Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients

Program Goals The Incretin System Response to Oral Glucose Injected Incretinbased Agents GLP1 Receptor Agonists Oral Incretinbased Agents DPP4 Inhibitors Main Pathophysiological Defects in T2D. the Treatment of T1DM and T2DM. Lawrence Blonde, MD, FACP, FACE. Director of the . Ochsner. Diabetes Clinical Research Unit. Ochsner. Medical Center. New Orleans, Louisiana. Vivian . A. Fonseca, MD, FRCP. G. lucose . C. ontrol. Mary Catherine . MacSween. MD FRCPC. The Moncton Hospital . Case DM. 74 year old male DM1 x 40 years.. MDI with . Levemir. 17 units . hs. and . NovoRapid. at meals.. Pre-op instructions take half usual . Disclaimers. Program Goals. Initiation of Insulin Significantly Delayed in Many Patients. Percentage of Patients Achieving Glycemic Targets in Various Settings. Sequential Insulin Strategies in Type 2 Diabetes. NOT TOO HIGH…. NOT TOO LOW…. A PLAN FOR OPTIMIZING DIABETES MANAGEMENT . IN . NURSING HOMES. 5. . Insulin. : Part 1. Insulin. What you need to know. Part 1. Insulin. . produced in the . pancreas. Insulin and Incretins: the perfect Partnership? Stephen Colagiuri, MD Professor of Metabolic Health Boden Institute of Obesity, Nutrition and Exercise University of Sydney Sydney, Australia Moderator Associate Professor of Medicine. Clinical Director: Strelitz Diabetes Center. Eastern Virginia Medical School. Drugs, devices, and practice. DISCLOSURES. Served as a consultant to Sanofi-Aventis. PI on 2 clinical Trials (DPP4 – Takeda, SGLT2 – BI). Dr. . . Ghadiri. , MD. Assistance professor of endocrinology. Shahid. . Sadoughi. . University of Medical Sciences . 2. The importance of glycemic control in minimizing complications related to diabetes has been well established in type 1 diabetes . Basal-Bolus Insulin Therapy (BBIT). Tammy McNab MD FRCP(C). Objectives. To overview the current initiative to implement BBIT. To discuss caveats to insulin use. . as it impacts BBIT and perioperative glycemic control. Intensive Insulin Management 10Basal: Once-daily, either morning or bedtime(alternative: NPH morning and bedtime)Bolus: Fast-acting insulin before each meal;(alternative: R may be used)Premeal insulin Markus Menzen. 1. ; Niels Væver Hartvig. 2. ; Anne Kaas. 2. ; Nikoline Nygård Knudsen. 2. ; Johan Jendle. 3. 1. Division of Internal Medicine, Department of Gastroenterology and Diabetology, Community Hospital Bonn, Bonn, Germany. . Abdi. Endocrine . Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University of Medical Sciences. 16 February 2017. Outlines. Introduction to basal . insulins. Pharmacodynamics of basal . FOCUS OF PROFILE GLULISINE. The main target. To normalize . Blood glucose. Delay . progression. Reduce . complication. s. Diabetes Management. ᵛ. ᵛ. fasting. postprandial. 1.Fasting hyperglycemia . Dr. Sandra Neoh. , Endocrinologist. with thanks to . Dr. . Mervyn. . Kyi. , Endocrinologist. TNH Intern Teaching 2019. Point Prevalence Study. 351 patients (82% of all beds) across TNH, BHS, BECC surveyed. Research Institute For Endocrine Sciences. Endocrine Research Center. Shahid Beheshti University. 04.04.1397. Outlines. Case presentation. Barriers of insulin therapy. Action-profile. Types of basal .